BXPLANT is pleased to announce its official registration as a Contract Research Organization (CRO) with the Korea National Enterprise for Clinical Trials (KoNECT), marking a significant milestone in the company’s growth and recognition within Korea’s clinical trial ecosystem.
KoNECT is Korea’s premier national institution dedicated to supporting clinical trials, established to strengthen the global competitiveness of domestic clinical research and enhance the nation’s new drug development capabilities. As the leading government-backed organization in this field, KoNECT plays a pivotal role in advancing Korea’s position in the global pharmaceutical and biotechnology landscape.
This registration validates BXPLANT’s commitment to maintaining the highest standards of clinical development services and positions the company to participate more actively in national initiatives aimed at accelerating innovative therapeutics development. As a registered CRO with KoNECT, BXPLANT gains enhanced credibility and access to collaborative opportunities with leading pharmaceutical companies, research institutions, and emerging biotech ventures seeking reliable clinical development partners.
The recognition by KoNECT underscores BXPLANT’s expertise across the full spectrum of clinical development—from strategic planning and regulatory affairs to clinical operations and data management. This achievement reinforces the company’s mission to bridge R&D and clinical development through its unique CDRO model, ultimately contributing to Korea’s evolution as a global hub for drug development excellence.
BXPLANT remains committed to delivering world-class clinical development solutions and looks forward to leveraging this partnership with KoNECT to support more innovative projects that will bring transformative treatments to patients worldwide.
